Oragenics, Inc.
ONP-002
mild traumatic brain injury (mTBI)
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on ONP-002 for mild traumatic brain injury (mTBI) is expected Date TBD.
Primary source
· SEC 8-K
verified 14h ago
“If approved by the FDA, ONP-002 would be the first and only pharmacological standard of care for a global concussion market projected to reach over $9 billion by 2030.”